Dyslipidemia

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

PCSK9 inhibitor therapy within 24 hours after PCI was shown to bring LDL-C levels down closer to guideline-recommended goals.

An analysis of data from a Society of Vascular Surgeons registry is shedding light on the use of DAPT in patients following peripheral vascular interventions.

Results of the study suggest that patients with premature and extremely premature ASCVD are at risk for a higher accrued lifetime morbidity.

Full results of the phase 3 ELIPSE HoFH offer the greatest overview yet of the effects of evinacumab in patients with homozygous familial hypercholesterolemia.

A meta-analysis of 4 randomized trials is shedding light on the efficacy and safety of direct oral anticoagulant use for reducing recurrent VTE in patients with cancer.

Treatment with the PCSK9 Inhibitor did not increase risk of safety events, including new-onset diabetes.

A prespecified analysis of FOURIER is detailing the impact of evolocumab on CV events and LDL-C in patients with metabolic syndrome.

New data shows an adherence to troponin testing could complement optimized care.

The most common adverse events were injection-site reactions and headaches.

A new network meta-analysis offers an overview of the clinical benefit of less than 6 months, 6-month, 12-month, and extended periods of DAPT therapy after PCI with drug-eluting stents.

The model can simulate treatment benefit over time with time-varying low-density lipoprotein cholesterol.

S. Claiborne Johnston discusses the results of the phase 3 THALES trial examining use of ticagrelor dual antiplatelet therapy for reducing subsequent stroke in patients with AIS or TIA.

A prespecified analysis of ISAR-REACT 5 is shedding light on the effectiveness and safety of age- and weight-adjusted prasugrel versus ticagrelor following ACS.

A secondary ACCELERATE assessment shows a particular set of patients who may benefit from Lp(a)-lowering novel agents.

Results of the phase 3 THALES trial detail the effect of ticagrelor DAPT for reducing the risk of stroke and death in patients with acute ischemic stroke or transient ischemic attack.

New data suggests heparin could mitigate SARS-CoV-2 ability to bind to human cells.

The practice of genetic testing has been useful in clinically addressing found cases of familial hypercholesterolemia, among other conditions, but no clinical practice guidelines currently exist for testing patients with suspected hereditary dyslipidemia.